Taking a bigger dose of psilocybin does necessarily mean healing more. In fact, the dose you need might depend entirely on what you’re trying to fix.
A new study published in the Journal of Psychopharmacology just dropped some of the clearest evidence yet that psilocybin doesn’t work like a volume knob, where you just crank it up and get more of the same effect. Instead, different doses appear to unlock entirely different biological and behavioural outcomes.
Moderate doses reduced anxiety. Higher doses tackled depression. And the brain changes underlying each were happening in different regions.
The psilocybin mystery
We’ve all heard the headlines by now. Psilocybin is showing extraordinary promise for treatment-resistant depression. One or two sessions can produce relief that lasts weeks, sometimes months. The clinical trials are piling up, and they’re hard to argue with.
But there’s still lots we don’t understand about how it actually works.
I mean, a compound that leaves your body within hours somehow rewires your mood for months afterwards. That’s not how most drugs work. That’s not how most anything works. And yet the therapeutic effects are real, measurable, and persistent.
Connor Maltby, head of Translational Medicine at Ulysses Neuroscience Ltd and lead author of the study, put it plainly: the field needs to move beyond knowing that psychedelics work and start understanding how much receptor activation is needed to produce which kind of therapeutic effect.
That’s a shift in thinking from “this thing seems promising” to “we can actually build precise treatments with this.”
The study
Maltby and his team ran a series of experiments on mice.
First, they mapped out receptor occupancy – essentially, what percentage of serotonin 5-HT2A receptors (the brain’s primary psychedelic target) were actually being activated at different doses. They gave groups of mice doses ranging from 0.1 to 10 mg/kg and used radioactive tracers to measure binding in the prefrontal cortex.
Then they tracked the head twitch response, which is a well-established physical indicator that hallucinogenic-like effects are kicking in. High-speed cameras and AI tracking counted every twitch over 20-minute windows.
They tested anxiety-like behaviour using an elevated maze. Mice naturally avoid open, exposed walkways, so spending more time in them signals reduced anxiety. Separately, they used a forced swim test to gauge depression-like behaviour, where less passive floating suggests a more active, less “depressed” state.
The results were not what you’d expect if you assumed bigger dose = bigger benefit.
The Findings
Moderate doses (around 1.5 mg/kg) reduced anxiety-like behaviour. Mice spent more time in open, exposed areas of the maze – something they’d normally avoid. But the higher dose? No anxiety reduction at all.
Higher doses (3 mg/kg) reduced depression-like behaviour. Mice in the forced swim test were more active, less passive. But the moderate dose? No effect on depression measures.
Read that again. The moderate dose helped with anxiety but not depression. The high dose helped with depression but not anxiety. Different doses, different therapeutic outcomes.
And the brain data backed this up beautifully.
When the researchers examined the mice’s brains, they found that both doses made microtubules (the structural scaffolding inside neurons) more dynamic and flexible in the prefrontal cortex and the amygdala. That’s a sign of neuroplasticity, the brain’s ability to rewire itself.
But actual increases in synaptic proteins (the markers of new neural connections being formed) only showed up in the prefrontal cortex. Not in the amygdala. The researchers suggest this might be a kind of built-in safety mechanism, where the brain allows rewiring in regions involved in complex thought and mood regulation, while being more conservative in areas tied to fear processing. It’s as if the brain is saying: let’s grow new connections where it helps, but let’s not accidentally build new anxiety pathways.
As Maltby noted, this suggests the brain’s response to psychedelics isn’t globally uniform. It’s region-specific, and different regions may support different therapeutic outcomes.
Ego death or bust
There’s a pervasive assumption floating around psychedelic culture, and even in some clinical conversations, that the intensity of the trip correlates with the depth of the healing. Bigger experience, bigger breakthrough. Ego death or bust.
This study challenges that head-on.
What the data suggests is something far more nuanced: that the degree of receptor engagement determines the type of therapeutic effect, not just its magnitude. If your primary struggle is anxiety, a heroic dose might actually miss the target. If you’re battling entrenched depression, a moderate dose might not engage the biology you need.
Now, this was a mouse study. Mice can’t tell you they feel hopeless on a Tuesday afternoon for no reason. The behavioural tests are proxies, not perfect mirrors of human experience. Maltby himself was careful to note that these assays are best viewed as pharmacodynamic readouts rather than direct models of human emotion.
But, encouragingly, the levels of receptor occupancy associated with these effects in mice were broadly consistent with those linked to subjective and therapeutic effects in human imaging studies. That cross-species alignment suggests this framework might actually hold up when applied to people.
Where this is heading
The team plans to expand their research by testing psilocybin in animal models that include chronic stress and inflammation – conditions that much more closely mimic the biological features of clinical depression.
The long-term vision is understanding whether specific levels of receptor activation can be reliably linked to particular therapeutic outcomes. If that pans out, it could inform the development of next-generation psychedelic-derived compounds. Potentially ones that deliver the neuroplasticity benefits with reduced or even eliminated hallucinogenic effects.
We’re moving, slowly but measurably, from the era of “psychedelics seem to help” into the era of “here’s exactly how much, where in the brain, and for what condition.”
And that transition is needed.
The Bottom Line
More isn’t automatically better. The right dose depends on what you’re treating. And the brain is far more selective about where it allows psychedelic-driven rewiring than we previously assumed.
The study — “An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice” — was authored by Connor J. Maltby, Adam K. Klein, Enya Paschen, Jessica Pinto, Dino Dvorak, Joseph R. Hedde, Ashley N. Hanks, Massimiliano Bianchi, and Zoë A. Hughes.
Want to stay across the science that actually matters in psychedelic research — without the hype? The Spore Report breaks down the latest findings so you can separate signal from noise. Join the newsletter.
